bms-986218
mAbexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 28, 2017 (NCT03110107)
Timeline
Indications
Mechanism of action
- Cytotoxic T-lymphocyte protein 4INHIBITOR
CTLA4 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- bms-986218
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05169684 | Phase 2 | Feb 14, 2022 | Bristol-Myers Squibb |
| NCT04785287 | Phase 1/Phase 2 (Phase 2) | Mar 29, 2021 | University of Texas at Houston |
| NCT04301414 | Early Phase 1 (Phase 1) | Mar 11, 2020 | Bristol-Myers Squibb, Columbia University, Ferring |
| NCT03110107 | Phase 1/Phase 2 (Phase 2) | Apr 28, 2017 | Bristol-Myers Squibb |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 3 | 2 | 2 | 2017 |
| Columbia University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Ferring | For profit | 1 | 0 | 1 | 2020 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2021 |
4 organizations
Page 1 / 1